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Abstract
Background: Participant attrition in longitudinal studies can introduce systematic bias, favoring participants who
return for follow-up, and increase the likelihood that those with complications will be underestimated. Our aim was
to examine the effectiveness of home follow-up (Home F/U) to complete the final study evaluation on potentially
“lost” participants by: 1) evaluating the impact of including and excluding potentially “lost” participants (e.g., those
who required Home F/U to complete the final evaluation) on the rates of study complications; 2) examining the
relationship between timing and number of complications on the requirement for subsequent Home F/U; and 3)
determining predictors of those who required Home F/U.
Methods: We used data from a randomized controlled trial (RCT) conducted from 1991–1994 among coronary
artery bypass graft surgery patients that investigated the effect of High mean arterial pressure (MAP) (intervention)
vs. Low MAP (control) during cardiopulmonary bypass on 5 complications: cardiac morbidity/mortality, neurologic
morbidity/mortality, all-cause mortality, neurocognitive dysfunction and functional decline. We enhanced
completion of the final 6-month evaluation using Home F/U.
Results: Among 248 participants, 61 (25%) required Home F/U and the remaining 187 (75%) received Routine F/U.
By employing Home F/U, we detected 11 additional complications at 6 months: 1 major neurologic complication,
6 cases of neurocognitive dysfunction and 4 cases of functional decline. Follow-up of 61 additional Home F/U
participants enabled us to reach statistical significance on our main trial outcome. Specifically, the High MAP group
had a significantly lower rate of the Combined Trial Outcome compared to the Low MAP group, 16.1% vs. 27.4%
(p=0.032). In multivariate analysis, participants who were ≥ 75 years (OR=3.23, 95% CI 1.52-6.88, p=0.002) or on
baseline diuretic therapy (OR=2.44, 95% CI 1.14-5.21, p=0.02) were more likely to require Home F/U. In addition,
those in the Home F/U group were more likely to have sustained 2 or more complications (p=0.05).
Conclusions: Home visits are an effective approach to reduce attrition and improve accuracy of study outcome
reporting. Trial results may be influenced by this method of reducing attrition. Older participants, those with greater
medical burden and those who sustain multiple complications are at higher risk for attrition.
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Background
Attrition in longitudinal randomized controlled trials
(RCTs) is a challenge faced by every clinical investigator.
In studies of medical and surgical patients, participants
who are lost to follow-up have distinct characteristics,
including worse functional outcomes, new complications
or death [1-3]. It has been suggested that attrition of 5%
or less is unlikely to introduce bias, and conversely, attri-
tion rates of 20% or more raise concerns about validity
[4]. In a review of RCTs reporting time to event out-
comes in 4 leading medical journals, only 44% published
detailed and consistent loss to follow-up information [5].
A review that examined missing outcome data in RCTs
published in 4 major medical journals found that 89% of
studies had some missing outcome data and 18% of
studies had more than 20% of participants with missing
outcome data [6]. Some journals will not publish RCTs
with attrition that exceeds 20% [7]. Attrition is therefore
a major concern for RCTs as it raises important meth-
odological questions, such as, what was the clinical
course of participants who are missing or have dropped
out and what would be the effect if missing or “lost” par-
ticipants could be located and included in the reporting
of study outcomes (i.e., complication rates)?
Study attrition creates bias in the direction of those
who complete participation in longitudinal studies.
Complications such as mortality are found only with in-
tensive efforts focused on obtaining complete follow-up,
and the complication rate for a group of participants can
dramatically shift when potentially lost participants are
ultimately located and included in the analysis [2]. Thus,
when high attrition rates are present, there is the likeli-
hood that those participants with complications have
been underestimated. In a longitudinal study of patients
who had undergone total hip replacement, Murray and
colleagues found that participants lost to follow-up had
significantly worse pain, less movement, as well as worse
progress and radiological scores at their last recorded
visit when compared to participants who completed
follow-up [8].
Since the late 1980’s, there has been great interest in
neurocognitive complications following cardiac surgery.
Over the intervening years, percutaneous coronary inter-
ventions (e.g., angioplasty, stenting and minimally inva-
sive procedures) have grown in popularity; traditional
cardiac surgical revascularization is now performed less
frequently, and reserved for those with diffuse triple ves-
sel or left main disease, particularly in the setting of dia-
betes [9]. One reason why Home F/U is particularly
important is that other cardiac surgery studies that have
assessed longitudinal neurocognitive functioning over
6–12 months post-operatively have reported loss to
follow-up ranging from 25-44% [10-12]. To our know-
ledge, no other studies have focused on increasing
follow-up in cardiac surgery studies in general, and on
improving neurocognitive follow-up, in particular.
Our study had 3 objectives: 1) to evaluate the impact
of including and excluding potentially “lost” participants
(e.g., those who required Home F/U in order to complete
the final 6-month study evaluation) on the rates of
reported study complications; 2) to examine the relation-
ship between the timing and number of complications
and the requirement for Home F/U; and 3) to determine
predictors of participants who required Home F/U.
Methods
Participants were primary elective CABG surgery
patients who had participated in a prospective RCT
examining the impact of intraoperative hemodynamic
management on major cardiac and neurologic morbid-
ity/mortality, all-cause mortality, neurocognitive dys-
function and deterioration in functional status [13].
Eligible participants were those scheduled to undergo
elective or urgent multi-vessel CABG for left main or
multi-vessel coronary artery disease. We have previously
described the details of eligibility [13]. All participants
provided informed written consent. We enrolled 248 par-
ticipants between 1991 and 1994. We previously reported
the RCT results with an intention-to-treat analysis [13].
The protocol, “Improving Outcomes and Quality of Life
after CABG” (IRB # 0689–579) was approved by the
Weill Cornell Institutional Review Board (IRB) in 1991
and the protocol has remained active and approved. The
data are held in the Division of Clinical Epidemiology
and Evaluative Sciences Research at Weill Cornell
Medical College.
Baseline, peri- and post-operative evaluations
The baseline evaluation has been reported elsewhere
[13]. In brief, prior to surgery, we collected demographic
and clinical characteristics of the participants by inter-
view, including their clinical history, medications and
the Charlson Comorbidity Index [14]. All participants
received standardized baseline cardiologic and neuro-
logical examinations. We assessed neurocognitive func-
tion with an eleven-test neuropsychologic battery
(WAIS-R Digit Span, Trail Making A and B, Boston
Naming, Benton Visual Retention and Recognition Test,
Controlled Oral Word Association, WAIS-R Digit
Symbol, Mattis-Kovner Verbal Recall and Recognition
and Finger Tapping Test). The Ammons Quick Test [15]
was used as a proxy for verbal IQ. We also collected
laboratory and electrocardiographic data.
We followed participants peri- and post-operatively
according to a standardized surveillance protocol. Re-
search assistants were present in the operating room
and recorded all events (e.g., blood pressures, duration
of cardiopulmonary bypass and number of bypass
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grafts). We have previously reported details of the
anesthetic protocol [16]. The study cardiologist and
neurologist, who were blinded to the intra-operative
treatment protocol, performed standardized evaluations
at 1, 2 and 7 days post-operatively (e.g., duration of
endotrachial intubation, amount of blood loss and length
of stay) and at 6 months. Final study complications (i.e.,
main trial outcomes) were assessed at 6 months.
We now present a secondary data analysis of this
RCT according to method of follow-up (Routine F/U
vs. Home F/U) required to complete the 6-month
final evaluation. The 5 trial complications (i.e., main
trial outcomes) were: 1) cardiac morbidity and mortal-
ity (i.e., myocardial infarction, low flow state/cardio-
genic shock, cardiopulmonary arrest, adult respiratory
distress syndrome and pulmonary edema); 2) neuro-
logic morbidity and mortality (i.e., major focal deficit);
3) all-cause mortality; 4) neurocognitive dysfunction (i.e.,
deterioration in ≥ 3 tests in the 11 test neurocogni-
tive battery); and 5) functional decline (i.e., > 5 point
decline in the physical component summary measure
of the SF-36 Health Survey [17-19]). We have previ-
ously described these complication definitions in detail
[13].
With regard to power in the original RCT, we had esti-
mated that the combined incidence of cardiac morbidity/
mortality, neurologic morbidity/mortality, all-cause mor-
tality, cognitive dysfunction and deterioration in func-
tional status would be 35%. To compensate for the
multiple complications without inflating the Type I error,
a conservative Bonferroni correction (0.005) was applied.
A drop in the incidence of any of the complications
(delta) of 0.20 constituted a clinically important differ-
ence between the High and Low MAP strategies. Based
on these estimated values of incidence, along with the
specified delta and alpha with 80% power, the sample size
estimate was 248 participants, or 124 in each group. We
sought to enroll a sufficient number of participants to
achieve 6-month follow-up on this sample size.
Randomization arms
Participants were randomized to one of two strategies of
hemodynamic management during cardiopulmonary
bypass. In the control group, we maintained participants’
mean arterial pressure (MAP) during cardiopulmonary
bypass at 50–60 mm Hg (usual care, “Low MAP”). In the
experimental group, we increased MAP during cardio-
pulmonary bypass to 80–100 mm Hg (“High MAP”).
Final study evaluation at 6 months
At 5 months, we contacted participants and asked them
to return to the hospital for the final study evaluation
(Routine F/U approach).
Routine F/U
We accommodated participant preferences, including
evening and weekend appointments, and reimbursed all
travel-related expenses. At this evaluation, we assessed
participants for interval clinical events using a standar-
dized set of questions, the blinded assessors performed
standardized cardiac and neurological exams, and neuro-
cognitive tests and questionnaires were re-administered
(e.g., SF-36 Health Survey). We also obtained an
electrocardiogram.
Home F/U
For participants who refused to schedule a Routine F/U
appointment or who missed at least two scheduled
appointments, we offered Home F/U. Home F/U con-
sisted of the same study personnel traveling to the parti-
cipant’s home or office to perform the study evaluation.
To minimize time outside of the office, we grouped the
visits by geographic location. After the visit, we con-
tacted the patient’s physician to obtain a copy of the
participant’s most recent electrocardiogram.
Statistics
We used SAS (SAS 9.2, Cary, NC) for data analysis.
Counts and percentages were calculated for the Routine
F/U and Home F/U participants. For continuous vari-
ables (e.g., age, ejection fraction and the neurocognitive
tests), we calculated means and standard deviations. For
highly skewed data, we calculated the median and range.
Variables such as age and the Charlson Comorbidity
Index were categorized according to clinically important
thresholds [20]. To evaluate difference between groups,
we compared continuous variables with Student’s t-test,
proportions using chi-square or Fisher’s exact test and
ordinal or highly skewed data with the Wilcoxon rank-
sum test. We also employed multivariate logistic regres-
sion and assessed the adequacy of the models using a
Hosmer and Lemeshow type residual analysis [21].
Objective 1: In order to evaluate the impact of
including and excluding potentially “lost” participants
on the reporting of study complication rates, we first
analyzed study complication rates by randomization
group (High vs. Low MAP) in Routine F/U participants
only. Had only Routine F/U been performed, study
surveillance at days 1, 2 and 7 would have been
conducted on all 248 participants and surveillance at 6
months would have been completed on the 187
participants who returned for Routine F/U. Five
participants sustained early complications and were not
in the Routine F/U group, bringing the total n to 192
for Routine F/U. To evaluate differences between the
groups, we compared proportions using chi-square or
Fisher’s exact test.
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For all analyses of complications, each patient was
counted only once. That is, for any of the 5
complications (cardiac complications, neurologic
complications, all-cause mortality, neurocognitive
dysfunction and functional decline) each patient was
counted as meeting each complication criteria in a
dichotomous +/− fashion. For example, if a patient
sustained more than 1 cardiac complication, we
counted the patient as meeting the criteria only once.
In addition, in the final analysis, if a patient
experienced any of the 5 complications, they were
counted as experiencing the main study outcome
(i.e., “Combined Trial Outcome”) in a dichotomous +/−
fashion. Thus, in the main trial analysis, no patient was
counted twice.
We next analyzed the same trial results (High vs. Low
MAP) with the combined cohort: both the Routine F/U
and Home F/U participants. This evaluation included
all 248 participants in the early evaluation and 237
participants who completed the late, 6-month
evaluation. Again, to evaluate differences between the
randomization groups, we compared proportions using
chi-square or Fisher’s exact test.
Objective 2: To examine the timing of complications
relative to the need for Home F/U, we compared the
rates of early and late complications in the Routine F/U
and Home F/U participants. Specifically, we evaluated:
1) combined early cardiac and neurologic morbidity
and mortality; 2) combined late (6-month) cardiac and
neurologic morbidity and mortality; and 3) the overall
rate of combined cardiac and neurologic morbidity and
mortality between the 2 F/U groups. We used chi-square
or Fisher’s exact test to examine proportions. Finally, we
examined the rate of major cardiac/neurologic
complications in the High MAP group in the Routine
F/U and Home F/U participants and the rate of major
cardiac/neurologic complications in the Low MAP group
in the Routine F/U and Home F/U participants with
chi-square and Fisher’s exact test. To examine whether
number of complications was related to the need for
Home F/U, we first tested the distribution of the number
of complications (range 0–3) over 6 months in the
Routine F/U and Home F/U groups using the Wilcoxon
rank-sum test. We next examined the distribution of the
number of complications in each F/U group by
randomization (High vs. Low MAP). Finally, we
evaluated the proportion of patients who sustained 2
or more complications by F/U group using the mid-p
exact test [22].
Objective 3: To determine predictors of participants
who required Home F/U, we employed multivariate
logistic regression. We evaluated various models to
assess the existence of possible interactions using
logistic regression and model fit statistics. We
employed multivariate logistic regression with Home
F/U as the dependent variable, controlling for baseline
comorbidity, (natural log) transformed hospital length
of stay and randomization group. In all analyses, we
counted the number of participants with events, not
the number of events. No data were imputed.
Results
The study population consisted of 248 participants.
Overall, 61 participants (25%) required Home F/U to
complete the 6-month evaluation. The remaining 187
participants (75%) received Routine F/U; 169 participants
(68%) returned to the hospital to complete the 6-month
evaluation, 7 (3%) died and 11 (4%) were lost.
Baseline and peri-operative characteristics
Table 1 shows the baseline demographic and clinical
characteristics for Routine F/U and Home F/U patients
according to randomization group (Low vs. High MAP).
Overall, the population had a mean age of 66 years and
was predominantly Caucasian. Over 70% were married
and over 47% had completed college. Participants
reported having cardiovascular disease for an average of
5.2 years, 43% had a history of a previous myocardial in-
farction and 20% had a history of diabetes mellitus.
There were baseline differences between the Routine F/U
and Home F/U participants. Specifically, Home F/U par-
ticipants were more likely to be 75 years or older
(p=0.006) and receiving diuretic therapy (p=0.04), how-
ever, 70% of those on diuretics did not have congestive
heart failure (CHF). In addition, Home F/U participants
had significantly lower scores at baseline on the Ammons
IQ test (p=0.04), Benton recognition (p=0.02), Trails B
(p=0.04) and Digit Symbol (p=0.04) tests.
With respect to differences in baseline characteristics
between the Routine F/U and Home F/U patients
according to randomization group (Low vs. High MAP)
(Table 1), participants who received Routine F/U and
were randomized to High MAP were more likely to have
COPD or asthma (p<0.04) when compared to those ran-
domized to Low MAP. Participants who received Home
F/U and were randomized to High MAP group were
more likely to be married (p=0.03), take nitrates
(p=0.01), be free of left main disease (p=0.04) and score
higher on the Digit Symbol test (p=0.04) when com-
pared to those randomized to Low MAP.
We also evaluated peri- and post-operative characteris-
tics to see if there were differences between the Routine
F/U and Home F/U participants. The groups were similar
with respect to number of bypass grafts placed during
surgery, duration of time on cardiopulmonary bypass,
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Table 1 Baseline demographic and clinical characteristics for Routine F/U and Home F/U patients according to
randomization group in the original RCT
ROUTINE F/U, N=187 HOME F/U, N=61
% unless otherwise indicated % unless otherwise indicated









Age, mean years (SD) 65.2 (9.3) 65.2 (10.1) 65.3 (8.4) 67.7 (9.5) 70.0 (9.5) 65.9 (9.3)
75 years and older 13.9 16.5 11.1 29.5 40.7 20.6
Male 78.6 78.3 78.9 83.6 78.8 88.2
Caucasian 95.6 94.6 96.6 98.3 96.3 100
College education or higher 48.4 50.5 46.0 44.8 41.7 47.1
Married 73.3 73.2 73.3 77.0 63.0 88.2*
Cardiac and Neurologic History
Cardiac symptom duration,
mean years (SD)
5.0 (7.1) 5.3 (7.6) 4.7 (6.7) 5.7 (8.6) 5.6 (8.4) 5.9 (8.8)
Current and former smokers 72.7 71.1 74.4 78.7 81.5 76.5
Canadian cardiovascular class
I 18.7 19.6 17.8 13.1 14.8 11.8
II 22.5 24.7 20.0 27.9 25.9 29.4
III 12.3 11.3 13.3 16.4 29.6 5.9
IV 27.8 30.9 24.4 16.4 14.8 17.7
Ejection Fraction, mean (SD) 48.5 (12.1) 49.3 (12.1) 47.6 (12.2) 47.4 (13.9) 47.2 (15.1) 47.6 (13.0)
Left main disease 13.9 14.4 13.3 11.5 22.2 2.9*
Previous MI 42.3 36.1 48.9 44.3 44.4 44.1
Congestive heart failure 10.7 10.3 11.1 11.5 14.8 8.8
COPD/Asthma 10.7 6.2 15.6* 6.6 7.4 5.8
Peripheral vascular disease 21.9 23.7 20.0 16.4 22.2 11.8
CVA 11.8 8.3 15.6 8.2 7.4 8.8
Charlson Comorbidity Score
0-1 58.8 58.8 58.9 54.1 48.1 58.8
2-3 27.8 27.8 27.8 36.1 44.4 29.4
≥ 4 13.4 13.4 13.3 9.8 7.4 11.8
Hypertension 49.2 43.3 55.6 59.0 59.3 58.8
Dialysis 1.6 2.1 1.1 0 0 0
Renal dysfunction 5.9 6.2 5.6 4.9 3.7 5.9
Diabetes 20.3 23.7 16.7 19.7 18.5 20.6
End organ damage 44.7 43.5 46.7 33.3 40.0 28.6
Medications
Diuretics 16.0 16.5 15.6 27.9 33.3 23.5
Calcium channel blockers 62.6 60.8 64.4 63.9 55.6 70.6
Nitrates 55.1 60.8 48.9 52.5 70.4 38.2*
Beta blockers 57.8 55.7 60.0 52.5 48.2 55.9
Ace inhibitors 16.6 17.5 15.6 16.4 22.2 11.8
Neurocognitive tests
Ammons IQ Test, mean (SD) 106.6 (14.4) 107.2 (15.5) 106.0 (13.3) 102.3 (12.2) 100.2 (10.5) 103.9 (13.2)
Linguistic Function
Boston Naming Test, median (range) 26.0 (8–30) 26.0 (8–30) 26.0 (11–30) 25 (9–30) 25 (12–30) 25 (9–30)
Controlled Word Association, mean (SD) 38.4 (13.4) 38.4 (13.5) 38.4 (13.3) 35.1(12.6) 34.2 (11.4) 35.7 (13.5)
Peterson et al. BMC Medical Research Methodology 2012, 12:178 Page 5 of 12
http://www.biomedcentral.com/1471-2288/12/178
duration of endotracheal intubation, amount of early
post-operative blood loss and overall hospital length of
stay (Table 2). When we examined the peri-operative
characteristics in the Routine F/U and Home F/U partici-
pants according to randomization group (Low vs. High
MAP) participants in the Routine F/U group who were
randomized to High MAP received fewer bypass grafts
during surgery (p=0.02) and had less blood loss in the
initial 24 hours after surgery (p=0.03) (Table 2). There
were no such differences noted between the Low and
High MAP groups in the Home F/U participants.
Main trial complication rates
Displayed in Table 3 are the rates of peri-operative and
6-month cardiac and neurologic complications, neurocog-
nitive dysfunction, functional decline and the Combined
Trial Outcome when only the Routine F/U participants
were considered. Table 4 displays the RCT trial results
with the inclusion of both the Home F/U and Routine
F/U groups. There are several notable differences between
Table 3 and Table 4. First, as a result of conducting Home
F/U, we were able to document 1 new case of major
neurologic morbidity, 6 additional cases of neurocognitive
dysfunction and 4 additional cases of functional decline
(n=11) (Table 4). Overall, this resulted in 4 additional
Combined Trial Outcomes, given that a single participant
may have sustained multiple complications (Table 4). Se-
cond, and more importantly, including Home F/U partici-
pants enabled us to reach statistical significance in our
Combined Trial Outcome, with the High MAP group ha-
ving a significantly lower rate of complications when com-
pared to the Low MAP group, 16.1% vs. 27.4% (p=0.032)
(Table 4). In contrast, when we conducted this same ana-
lysis in Routine F/U participants only, the analysis did not
reach statistical significance: 19.8% vs. 31.7% (p=0.061)
(Table 3).
Timing of complications
We next assessed the timing of complications to evaluate
whether complications were associated with the need for
a Home F/U. As shown in Table 5, most major cardiac
and neurologic complications occurred peri-operatively
and the rates of early and late complications did not differ
between the 2 F/U groups. Specifically, the rate of peri-
operative cardiac and neurologic complications was 6.4%
vs. 8.2% (p=0.82) and late complications (6 months) was
Table 1 Baseline demographic and clinical characteristics for Routine F/U and Home F/U patients according to
randomization group in the original RCT (Continued)
Memory
Benton Visual Recall, mean (SD) 5.2 (2.2) 5.3 (2.1) 5.1 (2.3) 4.6 (2.2) 5.0 (1.9) 4.3 (2.4)
Benton Recognition, median (range) 8 (3–10) 8 (3–10) 8 (4–10) 7.5 (0–10) 7 (3–10) 8 (0–10)
Mattis-Kovner Recall, mean (SD) 10.7 (3.4) 10.9 (3.4) 10.6 (3.4) 9.9 (3.6) 9.6 (4.0) 10.3 (3.2)
Mattis-Kovner, mean (SD) 2.7 (0–3.9) 2.7 (0–3.9) 2.7 (0–3.9) 2.6 (1.2-3.9) 2.4 (1.3-3.9) 2.7 (1.2-3.9)
Recognition, median (range)
Psychomotor function
Trails A, median (range) 40 (15–162) 38.5 (15–162) 41 (20–141) 39 (17–217) 39 (19–100) 41.5 (17–217)
Trails B, median (range) 86 (32–350) 85.0 (32–350) 89.5 (42–320) 104.5 (38–405) 117 (42–405) 92 (38–309)
Digit Symbol, mean (SD) 42.1 (12.3) 42.7 (13.6) 41.5 (10.7) 38.2 (11.9) 34.7 (12.3) 41.2 (10.9)*
Digit Span, mean (SD) 14.7 (4.1) 15.2 (4.0) 14.1 (4.1) 14.0 (3.7) 13.3 (3.5) 14.5 (3.8)
Finger Tapping Dominant, mean (SD) 47.1 (10.6) 47.0 (10.6) 47.2 (10.6) 44.2 (8.4) 45.0 (8.9) 43.5 (8.1)
Finger Tapping Non-dominant, mean (SD) 42.5 (8.9) 42.1 (9.2) 43.1 (8.7) 40.7 (8.1) 42.0 (8.0) 39.6 (8.2)
*Indicates comparison of High vs. Low MAP p<0.05.
Table 2 Perioperative characteristics for Routine F/U and Home F/U patients according to randomization group in the
original RCT









Number of grafts, mean (SD) 3.0 (0.8) 3.1 (0.9) 2.9 (0.8)* 3.0 (0.8) 3.0 (0.8) 3.1 (0.8)
Time on cardiopulmonary bypass, mean minutes (SD) 89.1 (30.1) 92.7 (31.4) 85.1 (28.2) 81.2 (29.0) 77.2 (29.4) 84.3 (28.7)
Duration of endotrachial intubation, mean hours (SD) 29.2 (96.3) 22.0 (10.7) 37.2 (139.5) 25.4 (27.0) 32.1 (38.9) 19.8 (7.1)
Post-operative blood loss initial 24 h post-operatively,
mean milliliters (SD)
980 (667) 1070 (769) 855 (521)* 892 (389) 803 (293) 962 (442)
Hospital length of stay, (median days, range) 11.0 (4-93) 11.0 (5–93) 11.0 (4–89) 10.0 (6-35) 11.0 (6–35) 10.0 (8–21)
*Indicates comparison of High vs. Low MAP p<0.05.
Peterson et al. BMC Medical Research Methodology 2012, 12:178 Page 6 of 12
http://www.biomedcentral.com/1471-2288/12/178
Table 3 Trial outcomes in Routine F/U patients
CARDIAC AND NEUROLOGIC MORBIDITY AND MORTALITY (N=192) P # OF COMPLICATIONS




High MAP (n=91) 5.5% Perioperative 4
6 months 3
Total 5
Total Cardiac and neurologic morbidity and mortality 10.9% Total 21
Neurocognitive Dysfunction Cardiac and Neurologic Morbidity and Mortality at 6 months (n=166)
Low MAP 11.6% 0.68 6 months 10
High MAP 13.8% 6 months 11
Total 12.7% 21
Functional Decline at 6 months n=160)
Low MAP 9.4% 0.38 6 months 8
High MAP 5.3% 6 months 4
Total 7.5% 12
Combined Trial Outcome (n=192)
Low MAP 31.7% 0.061 32
High MAP 19.8% 18
Total 26.0% 50
(Surveillance on 248 participants perioperatively and 187 participants at 6 months).
Table 4 Trial outcomes in Routine F/U and Home F/U patients
CARDIAC AND NEUROLOGIC MORBIDITY AND MORTALITY (N=248) P # OF COMPLICATIONS




High MAP (n=124) 4.8% Perioperative 4
6 months 4
Total 6
Total Cardiac and neurologic morbidity and mortality 8.9% Total 22
Neurocognitive Dysfunction at 6 months (n=225)
Low MAP 12.4% 0.86 6 months 14
High MAP 11.6% 6 months 13
Total 12.0% 27
Functional Decline at 6 months (n=217)
Low MAP 8.3% 0.62 6 months 9
High MAP 6.5% 6 months 7
Total 7.4% 16
Combined Trial Outcome (n=248)
Low MAP 27.4% 0.032 34
High MAP 16.1% 20
Total 21.8% 54
(Surveillance on 248 participants perioperatively and 237 participants at 6 months).
MAP= Mean Arterial Pressure. Combined Trial Outcomes included the following complications at 6 months: cardiac morbidity (myocardial infarction, pulmonary
edema, adult respiratory distress syndrome and cardiogenic shock); neurologic morbidity (major focal deficit); all-cause mortality; functional decline (>5 point
decline in physical component summary measure of the SF-36); and neurocognitive deterioration (within-patient differences on an 11 test neurocognitive battery).
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2.7% vs. 4.9% (p=0.62) in Routine F/U vs. Home F/U parti-
cipants, respectively. The overall rate of combined (early +
late) cardiac and neurologic complications was also similar
in the 2 F/U groups: 8.6% (16/187) in the Routine F/U
group compared to 9.8% (6/61) in the Home F/U group
(p=0.76) (Table 5). We next evaluated whether there were
differences in the rates of major cardiac and neurologic
complications according to randomization group. The
rates of major complications in the Low (Routine F/U
12.4% vs. Home F/U 14.8%) and High MAP groups (Rou-
tine F/U 4.4% vs. Home F/U 5.9%) did not differ according
to F/U group (p=0.95 and p>0.99, respectively).
Multiple Complications
We next evaluated the number of complications accord-
ing to Routine F/U vs. Home F/U and randomization
group (Table 6). The distribution of the number of com-
plications at 6 months in the Routine F/U vs. Home F/U
participants was similar (p=0.22). There were also no
differences by randomization group. However, 2.1% of
Routine F/U participants and 8.1% of Home F/U partici-
pants sustained 2 or more study complications (i.e.,
major cardiac or neurologic morbidity and mortality, all-
cause mortality, neurocognitive dysfunction or func-
tional decline), a significant difference (p=0.05) (Table 6).
When we evaluated the combination of the most ser-
ious complications, an early major cardiac or neurologic
complication and a new 6-month major cardiac or neuro-
logic complication, 3 participants met this criteria; 2 in
the High MAP group and 1 in the Low MAP group (data
not displayed). Two of these participants were seen at 6
months with Home F/U and 1 with Routine F/U. Finally,
1 participant experienced combined early cardiac and
neurologic complications. This participant required Home
F/U at 6 months.
Predictors of Requiring Home F/U
In multivariate logistic regression, we evaluated predic-
tors of requiring Home F/U at 6 months. Table 7
demonstrates the multivariate results, along with the
odds ratio and 95% confidence intervals. Age 75 years or
older (OR=3.23, 95% CI 1.52-6.88, p=0.002) and baseline
diuretic therapy (OR=2.44, 95% CI 1.14-5.21, p=0.02)
were both significant. The c statistic value (a point esti-
mate of the area under a ROC curve) equal to 0.71
reveals that our model has good predictive ability.
Discussion
The current study illustrates the importance of obtaining
follow-up on participants who do not return for final
evaluation in an RCT by displaying the effect of inclu-
ding Home F/U participants in the final analysis vs.
not including them. By conducting Home F/U, we were
able to detect an additional 11 complications: 1 new
Table 5 Complications in Routine F/U and Home F/U patients according to randomization group
ROUTINE F/U, N=187 HOME F/U, N=61








Perioperative cardiac and neurologic morbidity and mortality 6.4 (12) 9.3 (9) 3.3 (3) 8.2 (5) 14.8 (4) 2.9 (1)
6-month cardiac and neurologic morbidity and mortality 2.7 (5) 3.1 (3) 2.2 (2) 4.9 (3) 3.7 (1) 5.9 (2)
Total cardiac and neurologic morbidity and mortality 8.6 (16) 12.4 (12) 4.4 (4) 9.8 (6) 14.8 (4) 5.9 (2)
Functional decline (6 months) 7.5 (12) 9.4 (8) 5.3 (4) 7.0 (4) 4.2 (1) 9.1 (3)
Neurocognitive dysfunction (6 months) 12.7 (21) 11.6 (10) 13.8 (11) 10.2 (6) 14.8 (4) 6.3 (2)
Total Combined Outcome 24.0 (45) 28.9 (28) 18.9 (17) 14.8 (9) 22.2 (6) 8.8 (3)
Complications were cardiac morbidity (myocardial infarction, pulmonary edema, adult respiratory distress syndrome and cardiogenic shock); neurologic morbidity
(major focal deficit); all-cause mortality; functional decline (>5 point decline in physical component summary measure of the SF-36); and neurocognitive
deterioration (within-patient differences on an 11 test neurocognitive battery).
Table 6 Number of complications in Routine F/U and
Home F/U patients according to randomization group in
the original RCT











0 71.1 (69) 81.1 (73) 77.8 (21) 91.2 (31)
1 26.8 (26) 16.7 (15) 11.1 (3) 2.9 (1)
2 2.1 (2) 2.2 (2) 11.1 (3) 0
3 0 0 0 5.6 (2)
Complications=Major cardiac and neurologic morbidity/mortality + all cause
mortality + neurocognitive dysfunction + functional decline.
Table 7 Multivariate model of predictors of Home F/U at
6 months*
Multivariate p Odds ratio
(95% Confidence Interval)
Baseline predictors
≥75 years of age 0.002 3.23 (1.52-6.88)
Pre-operative diuretic use 0.02 2.44 (1.14-5.21)




*Model adjusted for baseline comorbidity, (natural log) transformed hospital
length of stay and randomization group.
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neurologic complication, 6 neurocognitive complications
and 4 functional complications. With Home F/U, we
achieved 6-month follow-up on an additional 61 partici-
pants (25%) and detected an additional 4 Combined
Trial Outcomes. This resulted in statistical significance
between the 2 randomization groups in the Combined
Trial Outcome – Low MAP 27.4% vs. High MAP 16.1%,
(p=0.032) (Table 4). To our knowledge, this is the
first paper to report the effect of Home F/U on the
main trial outcome (i.e., Combined Trial Outcome) in
an RCT.
The implications of positive vs. negative trial results on
clinical practice are significant. This RCT was a seminal
study, and the first and only randomized study to test the
efficacy of High vs. Low MAP during cardiopulmonary
bypass in order to decrease morbidity and mortality asso-
ciated with CABG surgery [13]. At the time this study
was conducted (1991–1994), MAP during cardiopulmon-
ary bypass was routinely maintained at 50–60 mm Hg
and believed to be safe. The results of this study provided
the first evidence that lower blood pressure (Low MAP)
was associated with higher rates of cardiac and neuro-
logic complications in the setting of CABG surgery, and
moreover, that High MAP during CABG could both pro-
tect against cardiac and neurologic complications [13]
and be done safely [16]. Optimal blood pressure manage-
ment during CABG surgery is still debated 20 years later
[23,24]. However, it is now clear that high risk CABG
surgery patients require increased perfusion pressures
(High MAP) while on cardiopulmonary bypass, and
MAPs during CABG surgery are maintained higher today
than they were 20 years ago [23,25].
Advantages and disadvantages to Home F/U vs. Routine F/U
The most obvious advantage of the Home F/U approach is
enhanced follow-up of participants, resulting in decreased
selection bias (Tables 3 and 4). An alternative to Home F/
U to reach sample size is to continue enrolling new partici-
pants to replace participants who have not returned for
follow-up or who have dropped out. However, there is ex-
tensive evidence that lost participants are qualitatively dif-
ferent than participants who complete study follow-up. For
example, people who do not complete follow-up are more
likely to have sustained adverse outcomes, died or have
worse health and function [1-3]. We found that people
with 2 or more complications were more likely to require
Home F/U. Without Home F/U, the complications sustai-
ned by these participants (8.1%, see Table 6) would not
have been counted in our study results. Home F/U does
have disadvantages, including time intensity of the ap-
proach and cost. Another potential disadvantage may be
that the way participants answer study questions might be
different at home compared to in the hospital setting,
which is germane to the neurocognitive tests and quality of
life assessment (e.g. SF-36), but not assessment of clinical
complications.
In multivariate analysis, we found that Home F/U par-
ticipants had different demographic and clinical charac-
teristics when compared to Routine F/U participants –
at baseline they were more likely to be older and receiv-
ing diuretic therapy. Of the participants on diuretics,
70% did not have a history of CHF. We hypothesized
that because of their older age and medical illnesses re-
quiring diuretic therapy (e.g., refractory hypertension),
Home F/U participants were more likely sedentary with
other non-life-threatening chronic illnesses (conditions
not assessed by the Charlson Index, which only assesses
conditions that increase mortality risk) that made
returning to the hospital for 6-month follow-up difficult
(e.g., osteoarthritis).
Taken collectively, the most common predictors of
drop out are older age, cognitive dysfunction and func-
tional impairment. Older age is the most common factor
associated with loss to follow-up [26-30]. We found that
participants who were older were more likely to require
Home F/U, particularly participants who were 75 years
of age or older (OR=3.23, 95% CI 1.52-6.88). Cognitive
impairment is also a well-recognized predictor of loss to
follow-up [26]. Blumenthal found that cardiac surgery
patients who dropped out of a study of neurocognitive
functioning over time had lower baseline neurocognitive
scores when compared to those who completed 6-week
and 6-month evaluations [31]. We similarly found that
Home F/U participants scored lower at baseline on the
Ammons IQ test, the Benton recognition test, Trails B
and Digit Symbol (Table 1). However, neurocognitive
function was not a significant predictor of the need for
Home F/U in our multivariate model (Table 7).
Participants who drop out of epidemiologic studies
have worse health and function. Mihelic and Crimmins
reported that having difficulty with activities of daily liv-
ing was predictive of drop out in an epidemiologic study
of older adults [28]. Markides [27] reported that drop
outs had lower self-rated health. Our study supports
this, as evidenced by the finding that Home F/U added 4
additional functional complications. In addition, we
found that participants requiring Home F/U were more
likely to have sustained 2 or more major complications
when compared to Routine F/U participants (p=0.05)
(Table 6). Finally, participants on diuretics prior to sur-
gery were 2.4 times more likely to require Home F/U at
6 months (OR=2.44, 95% CI, 1.14-5.21).
Limitations
Our study had several limitations. First, this RCT was
conducted 20 years ago and the cardiac surgery popula-
tion may be different now. Nonetheless, we believe that
the methodologic bias introduced as a result of drop
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outs is a timeless issue and that Home F/U remains a vi-
able strategy to achieve follow-up for missing partici-
pants in contemporary clinical research, particularly
because cardiac surgery patients are now older, with
greater comorbidity [9], which our findings suggest in-
crease the risk for attrition. Second, this was not an
RCT of Home F/U vs. Routine F/U. Therefore, the study
was not powered to examine the timing of complications
relative to potential loss to follow-up or formally estab-
lish clinical predictors of participants who required
Home F/U. Nonetheless, the study demonstrates the
methodologic importance of follow-up on RCT results
and the feasibility of Home F/U as a strategy to reduce
attrition. Third, responses to assessments may be differ-
ent in the patient’s home compared to what they might
have been in the hospital setting, but, as mentioned earl-
ier, this would only affect subjective measures.
Recommendations
We offer several recommendations to help prevent drop
out. Given the time and resources required to conduct
Home F/U, we have developed a number of strategies to
retain participants. We believe that by employing these
approaches, we decrease the likelihood that we will lose
participants over the course of a longitudinal study.
1. Inform participants of the study requirements and
ensure they are aware of the follow-ups that are
required [32].
2. Obtain alternate contacts; we recommend at least 2,
preferably 3, alternates who do not reside with the
participant.
3. Study personnel should strive to develop positive,
friendly relationships with participants, be helpful
and accommodating, allocate adequate time for
follow-ups, and schedule follow-ups on days and at
times that are convenient for participants, including
evenings and weekends.
4. Limit follow-up evaluations in length and frequency.
Schedule study follow-ups to coincide with other
routinely scheduled clinical appointments whenever
possible.
5. Refusal of 1 follow-up is not necessarily a dropout.
Moreover, when participants are at risk for
withdrawal, it is important to ascertain the reason.
Studies have found that life events, such as divorce
or retirement, may lead to study drop out [33]. It is
possible that participants will consent to being
contacted in the future, once the personal situation
has resolved [34].
6. Stay alert for participants who are “at risk” for
dropping out (e.g., failure to return calls, missing
appointments) [34]. If a participant refuses to return,
consider employing alternate sources of information
to ascertain clinical status (e.g., clinical notes). If a
participant does drop out, record detailed reasons.
Another alternative that has been suggested is
triggered sampling, where additional information is
collected when a designated health marker declines,
but prior to drop out [35].
7. Create an “essential evaluation” that has only
questions that are most critical to your study, which
can be employed with participants who are at high
risk of dropping out.
8. Finally, offer Home F/U to those participants who
are at risk of dropping out, particularly when
assessing final study complications.
Our study differs from other studies that have exam-
ined attrition. Because the participants have dropped out
in other studies, the participant’s health status with re-
spect to the study complications is unknown when they
have dropped out. In contrast, the current study pre-
sents a mechanism to decrease attrition and obtain
follow-up on participants who would likely have
dropped out of the study. In this manner, we are able to
add to the literature and report participant health status
at the point in time when they were at high risk for
dropping out of the study. These results were obtained
in the context of a study of CABG surgery patients.
However, we believe these results are generalizable to
other patient groups, and Home F/U should be consid-
ered a feasible approach to decrease study attrition in
longitudinal clinical research studies. We recommend
that intervention studies of clinical populations consider
home visits as a viable mechanism to decrease attrition
and improve longitudinal follow-up.
Conclusions
We have demonstrated that Home F/U is a feasible ap-
proach to achieve 4% loss to follow-up in a longitudinal
clinical trial. We found that the timing of complications
(early vs. late) was not related to the need for Home F/U,
but participants who sustained 2 or more complications
were significantly more likely to require Home F/U. In
addition, we found that participants in the Home F/U
group were more likely to be 75 years or older and on
diuretic therapy at baseline, indicating that these partici-
pants were both older and more medically ill at baseline.
The data that we examined for this paper was from a study
of CABG surgery patients conducted 20 years ago and this
was not a randomized comparison of Routine F/U vs.
Home F/U. Nonetheless, over the intervening years, the
issue of loss to follow-up remains an ongoing and critically
important methodological challenge in clinical research.
While new statistical procedures have been developed
to impute missing data over the intervening years, there
is no replacement for actual clinical data obtained from
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participants. Finally, we have offered recommendations
to decrease the likelihood of loss to follow-up over the
course of a longitudinal study.
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